Published in J Neuroimmunol on January 01, 1999
Pituitary adenylyl cyclase-activating polypeptide is an intrinsic regulator of Treg abundance and protects against experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (2009) 1.23
VIP and PACAP: neuropeptide modulators of CNS inflammation, injury, and repair. Br J Pharmacol (2013) 1.06
Anti-inflammatory role in septic shock of pituitary adenylate cyclase-activating polypeptide receptor. Proc Natl Acad Sci U S A (2002) 1.02
Vasoactive intestinal peptide loss leads to impaired CNS parenchymal T-cell infiltration and resistance to experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (2010) 0.97
Differential signaling of T cell generation of IL-4 by wild-type and short-deletion variant of type 2 G protein-coupled receptor for vasoactive intestinal peptide (VPAC2). J Immunol (2006) 0.89
VIP deficient mice exhibit resistance to lipopolysaccharide induced endotoxemia with an intrinsic defect in proinflammatory cellular responses. PLoS One (2012) 0.87
Vasoactive intestinal polypeptide enhances oral tolerance by regulating both cellular and humoral immune responses. Clin Exp Immunol (2007) 0.83
Toll-like receptor stimulation differentially regulates vasoactive intestinal peptide type 2 receptor in macrophages. J Cell Mol Med (2009) 0.82
Neuroimmune link in the mucosa of chronic gastritis with Helicobacter pylori infection. Dig Dis Sci (2006) 0.82
Vasoactive intestinal polypeptide promotes intestinal barrier homeostasis and protection against colitis in mice. PLoS One (2015) 0.81
Vasoactive intestinal peptide-deficient mice exhibit reduced pathology in trinitrobenzene sulfonic acid-induced colitis. Neuroimmunomodulation (2014) 0.80
Ocular and systemic bio-distribution of rhodamine-conjugated liposomes loaded with VIP injected into the vitreous of Lewis rats. Mol Vis (2007) 0.80
Nerve growth factor, neuropeptides and cutaneous nerves in atopic dermatitis. Indian J Dermatol (2010) 0.79
Functional splice variants of the type II G protein-coupled receptor (VPAC2) for vasoactive intestinal peptide in mouse and human lymphocytes. Ann N Y Acad Sci (2006) 0.78
Vasoactive intestinal Peptide inhaled agonists: potential role in respiratory therapeutics. Hippokratia (2013) 0.75
Decoding the chemokine network that links leukocytes with decidual cells and the trophoblast during early implantation. Cell Adh Migr (2016) 0.75
Administration of a vasoactive intestinal peptide antagonist enhances the autologous anti-leukemia T cell response in murine models of acute leukemia. Oncoimmunology (2017) 0.75
Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut (2009) 4.06
Antibacterial agents based on the cyclic D,L-alpha-peptide architecture. Nature (2001) 4.00
Complications associated with Brucella melitensis infection: a study of 530 cases. Medicine (Baltimore) (1996) 3.23
Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med (2001) 2.81
Shifts in clostridia, bacteroides and immunoglobulin-coating fecal bacteria associated with weight loss in obese adolescents. Int J Obes (Lond) (2008) 2.09
Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. Ann Rheum Dis (2010) 1.86
Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia (2010) 1.66
Recent improvement in long-term survival after a COPD hospitalisation. Thorax (2010) 1.65
Alkaline and neutral Comet assay profiles of sperm DNA damage in clinical groups. Hum Reprod (2012) 1.52
[Familial transmission of hepatitis C virus]. Rev Esp Enferm Dig (1996) 1.40
A real-coded genetic algorithm for training recurrent neural networks. Neural Netw (2001) 1.40
Gastrointestinal dysfunction in mice with a targeted mutation in the gene encoding vasoactive intestinal polypeptide: a model for the study of intestinal ileus and Hirschsprung's disease. Peptides (2007) 1.36
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies. J Immunol (1999) 1.35
Aberrant expression of tetraspanin molecules in B-cell chronic lymphoproliferative disorders and its correlation with normal B-cell maturation. Leukemia (2005) 1.29
Therapeutic effect of urocortin and adrenomedullin in a murine model of Crohn's disease. Gut (2006) 1.28
Mobilisation with G-CSF in healthy donors promotes a high but temporal deregulation of genes. Leukemia (2005) 1.27
Identification of laminin alpha1 and beta1 chain peptides active for endothelial cell adhesion, tube formation, and aortic sprouting. FASEB J (1999) 1.26
Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-alpha and IL-6. J Immunol (1999) 1.26
Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia. Leukemia (2005) 1.26
Prevention of endemic healthcare-associated Clostridium difficile infection: reviewing the evidence. Am J Gastroenterol (2010) 1.20
Influence of trial registration on reporting quality of randomized trials: study from highest ranked journals. J Clin Epidemiol (2010) 1.15
Mobilization of potent plasma bactericidal activity during systemic bacterial challenge. Role of group IIA phospholipase A2. J Clin Invest (1998) 1.15
Repair of single-stranded DNA nicks, gaps, and loops in mammalian cells. Mol Cell Biol (1987) 1.13
MRI shows abnormal white matter maturation in classical holoprosencephaly. Neurology (2002) 1.11
Cutting edge: is vasoactive intestinal peptide a type 2 cytokine? J Immunol (2001) 1.10
Strategic intervention: a mental health program for the Hispanic community. J Community Psychol (1979) 1.09
VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNgamma synthesis by T cells. J Neuroimmunol (1999) 1.09
Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases. J Mol Med (Berl) (2001) 1.08
Cardiac hemangioma. Ann Thorac Surg (1994) 1.07
Impaired nerve regeneration and enhanced neuroinflammatory response in mice lacking pituitary adenylyl cyclase activating peptide. Neuroscience (2007) 1.06
Distribution patterns of phosphorylated Thr 3 and Thr 32 of histone H3 in plant mitosis and meiosis. Cytogenet Genome Res (2008) 1.06
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit endotoxin-induced TNF-alpha production by macrophages: in vitro and in vivo studies. J Immunol (1999) 1.06
Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) mRNA in murine lymphocytes. J Neuroimmunol (1996) 1.06
Modulation of the balance between cannabinoid CB(1) and CB(2) receptor activation during cerebral ischemic/reperfusion injury. Neuroscience (2008) 1.05
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages. J Leukoc Biol (1998) 1.04
VIP-PACAP system in immunity: new insights for multitarget therapy. Ann N Y Acad Sci (2006) 1.03
Anti-inflammatory properties of the type 1 and type 2 vasoactive intestinal peptide receptors: role in lethal endotoxic shock. Eur J Immunol (2000) 1.02
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide stimulate the induction of Th2 responses by up-regulating B7.2 expression. J Immunol (1999) 1.02
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit nuclear factor-kappa B-dependent gene activation at multiple levels in the human monocytic cell line THP-1. J Biol Chem (2001) 1.02
Immunology of VIP: a review and therapeutical perspectives. Curr Pharm Des (2001) 1.02
Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vitro and in vivo. J Immunol (2001) 1.02
Induction of neuropeptide gene expression and blockade of retrograde transport in facial motor neurons following local peripheral nerve inflammation in severe combined immunodeficiency and BALB/C mice. Neuroscience (2004) 1.02
In vitro stimulatory effect of substance P on hematopoiesis. Blood (1993) 1.01
VIP down-regulates TLR4 expression and TLR4-mediated chemokine production in human rheumatoid synovial fibroblasts. Rheumatology (Oxford) (2005) 1.01
Immunobiology of vasoactive intestinal peptide (VIP) Immunol Today (2000) 1.01
Environment- and sequence-dependent modulation of the double-stranded to single-stranded conformational transition of gramicidin A in membranes. Biochemistry (1998) 1.00
Inhibition of IFN-gamma-induced janus kinase-1-STAT1 activation in macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. J Immunol (2000) 1.00
Modulation of established murine collagen-induced arthritis by a single inoculation of short-term lipopolysaccharide-stimulated dendritic cells. Ann Rheum Dis (2007) 0.98
HPLC study on the 'history' dependence of gramicidin A conformation in phospholipid model membranes. FEBS Lett (1989) 0.98
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: players in innate and adaptive immunity. Cell Mol Biol (Noisy-le-grand) (2003) 0.97
Carbon nanotubes randomly decorated with gold clusters: from nano2hybrid atomic structures to gas sensing prototypes. Nanotechnology (2009) 0.97
Addressing substrate glutamine requirements for tissue transglutaminase using substance P analogues. FEBS Lett (1999) 0.97
Lack of MHC class I antigens and tumour aggressiveness of the squamous cell carcinoma of the larynx. Br J Cancer (1990) 0.96
Pituitary adenylate cyclase-activating polypeptide inhibits collagen-induced arthritis: an experimental immunomodulatory therapy. J Immunol (2001) 0.96
Localized fibrous tumors of the pleura: experience with 7 recent cases. Arch Bronconeumol (2004) 0.95
Vasoactive intestinal peptide modulates proinflammatory mediator synthesis in osteoarthritic and rheumatoid synovial cells. Rheumatology (Oxford) (2003) 0.95
Receptors and transcriptional factors involved in the anti-inflammatory activity of VIP and PACAP. Ann N Y Acad Sci (2000) 0.94
Conformational transitions of gramicidin A in phospholipid model membranes. A high-performance liquid chromatography assessment. Biochemistry (1991) 0.94
Transcription termination within the Escherichia coli origin of DNA replication, oriC. Mol Gen Genet (1986) 0.94
Meiotic studies in two human reciprocal translocations and their association with spermatogenic failure. Hum Reprod (2005) 0.93
Core histones are glutaminyl substrates for tissue transglutaminase. J Biol Chem (1996) 0.93